DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cubicin (Daptomycin) - Published Studies

 
 



Cubicin Related Published Studies

Well-designed clinical trials related to Cubicin (Daptomycin)

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. [2010.06.15]

Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. [2009.07]

Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. [2009.05]

The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. [2009.03]

Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. [2008.12]

Clinical experience with daptomycin: bacteraemia and endocarditis. [2008.11]

Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. [2007.07]

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. [2006.10]

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. [2006.08.17]

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. [2005.02]

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. [2004.06.15]

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. [1992.02]

Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. [1989.10]

Well-designed clinical trials possibly related to Cubicin (Daptomycin)

Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. [2012]

New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. [2012]

Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. [2009.12]

Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. [2009.03.15]

Other research related to Cubicin (Daptomycin)

Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial. [2014]

Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. [2013]

Efficacy of daptomycin versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producers and methicillin-resistant Staphylococcus epidermidis. [2011.11.28]

Genetic basis for in vivo daptomycin resistance in enterococci. [2011.09.08]

Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? [2011.09]

In vitro activity and in vivo efficacy of the saponin diosgenyl 2-amino-2-deoxy-beta-D-glucopyranoside hydrochloride (HSM1) alone and in combination with daptomycin and vancomycin against Gram-positive cocci. [2011.09]

Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. [2011.07.15]

Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. [2011.07]

Reversible daptomycin tolerance of adherent staphylococci in an implant infection model. [2011.07]

Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. [2011.07]

[Methicillin-resistant Staphylococcus aureus: changes in the susceptibility pattern to daptomycin during a 10-year period (2001-2010)]. [2011.06]

Intravitreal daptomycin: a safety and efficacy study. [2011.06]

Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery. [2011.06]

Use of daptomycin in complicated cases of infective endocarditis. [2011.06]

Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. [2011.05]

Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. [2011.05]

Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. [2011.05]

Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin. [2011.05]

Emergence of daptomycin-resistant VRE: experience of a single institution. [2011.04]

Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. [2011.04]

Clinical experience with daptomycin in Europe: the first 2.5 years. [2011.04]

Lipopeptide Laur-CKK-NH2 dimer preserves daptomycin susceptibility and enhances its activity against Enterococcus faecalis. [2011.04]

Prospective, non-comparative study of daptomycin for the treatment of superficial and deep incisional surgical site infections. [2011.04]

[Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient]. [2011.03]

[Safety of daptomycin in patients with renal impairment]. [2010.12]

[Daptomycin in home hospitalization]. [2010.12]

[Role of daptomycin in the treatment of infections in patients with hematological malignancies]. [2010.12]

[Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient]. [2010.12]

[Clinical experience with daptomycin use in Spain. Global findings from EU-CORE database]. [2010.12]

[Methodology and aims of the European Cubicin(R) Outcome Registry and Experience (EUCORE) database]. [2010.12]

Safety and clinical outcomes among older adults receiving daptomycin therapy: Insights from a patient registry. [2010.12]

Daptomycin compared to standard therapy for the treatment of native valve endocarditis. [2010.10]

Daptomycin and Rifampin Alone and in Combination Prevent Vascular Graft Biofilm Formation and Emergence of Antibiotic Resistance in a Subcutaneous Rat Pouch Model of Staphylococcal Infection. [2010.09.22]

High-dose daptomycin in documented Staphylococcus aureus infections. [2010.09.14]

Characterization of skeletal muscle effects associated with daptomycin in rats. [2010.09]

[Possible daptomycin-induced organizing pneumonia] [2010.08.09]

A retrospective review of clinical experience with daptomycin for a variety of wound types in a burn and wound care facility. [2010.08]

Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis. [2010.07]

Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. [2010.06.01]

Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. [2010.06]

A potential role for daptomycin in enterococcal infections: what is the evidence? [2010.06]

Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. [2010.05]

Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. [2010.04]

Use of daptomycin in a pregnant patient with Staphylococcus aureus endocarditis. [2010.04]

Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties. [2010.04]

Relapse of enterococcal prosthetic valve endocarditis with aortic root abscess following treatment with daptomycin in a patient not fit for surgery. [2010.04]

Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. [2010.03.01]

Daptomycin: pharmacology and clinical use. [2010.03]

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008). [2010.03]

Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. [2010.03]

Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report. [2010.02.18]

Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. [2010.01.01]

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. [2010]

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. [2009.10]

Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. [2009.09.01]

Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. [2009.09]

Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. [2009.09]

Propionibacterium skull osteomyelitis treated with daptomycin. [2009.09]

Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. [2009.09]

Daptomycin for the treatment of surgical site infections. [2009.08]

Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. [2009.08]

Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. [2009.07.15]

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. [2009.07]

Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. [2009.07]

Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. [2009.07]

Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? [2009.07]

Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient. [2009.07]

Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. [2009.07]

Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. [2009.07]

Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. [2009.07]

[Infections in the immunocompromised host: role of daptomycin] [2009.07]

Activity of daptomycin against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae. [2009.06]

Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. [2009.06]

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). [2009.06]

A long-term retrospective review of 5 cases using daptomycin for prosthetic device infections after surgery. [2009.05]

Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. [2009.05]

Daptomycin in experimental murine pneumococcal meningitis. [2009.04.30]

Extremely low excretion of daptomycin into breast milk of a nursing mother with methicillin-resistant Staphylococcus aureus pelvic inflammatory disease. [2009.03]

In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. [2009.03]

In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece. [2008.12]

Daptomycin in bone and joint infections: a review of the literature. [2008.11.07]

Daptomycin in endocarditis and bacteraemia: a British perspective. [2008.11]

Pre-clinical experience with daptomycin. [2008.11]

Future directions with daptomycin. [2008.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017